Adding chemotherapy to surgery prolonged life in some lung, neuroendocrine cases

Share this article:

Perioperative chemotherapy may benefit persons with resected small-cell lung cancer (SCLC) or large-cell neuroendocrine carcinomas (LCNECs), indicates a retrospective analysis conducted in France and presented in Journal of Thoracic Oncology (2012;7[7]:1179-1183), which is published by the International Association for the Study of Lung Cancer (IASLC).

The review of patients who had undergone surgery for limited-stage SCLC or LCNEC showed that 45 had surgery combined with perioperative chemotherapy and 29 had surgery only. Eleven patients in the surgery-plus-chemotherapy group and four in the surgery-only group had LCNEC, which has characteristics similar to those of SCLC. Ten node-positive tumors and two incomplete resections were noted in the surgery group, compared with 27 node-positive tumors and three incomplete resections in the other patients.

Median follow-up was shorter for the surgery-only patients, at 4.5 years vs 5.8 years. Among the patients with a survival or a follow-up of at least 6 months, median survival was 2.3 years among 20 surgery patients, compared with a significantly longer 6.1 years for the 39 people who had surgery plus chemotherapy.

As noted in a statement from the IASLC, SCLC represents about 15% of all lung cancer cases annually. Approximately 30% of the members of that subset have limited-stage disease. Surgery in those patients as well as in persons with LCNEC is so rare that the investigators believe a prospective trial is unlikely to be feasible; therefore, these retrospective data may be of value despite the study's small size and other limitations.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Biomarker for aggressive, basal-like breast cancer identified

A biomarker strongly linked to basal-like breast cancer has been identified.

Tumor suppressor mutations alone do not explain deadly cancer

Although mutations in a gene dubbed the "guardian of the genome" are recognized as being associated with more aggressive cancers, evidence suggests that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities.

Triple therapy revs up immune system against a common brain tumor

A triple therapy for glioblastoma, consisting of two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report.